Guideline-Directed Medical Therapy for Heart Failure

Introduction to Target Doses

The American College of Cardiology recommends titrating patients to target doses of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality 1, 2

The American College of Cardiology recommends the following target doses for ACE inhibitors: Captopril 50 mg three times daily, Enalapril 10 mg twice daily, Lisinopril 20 mg once daily, Ramipril 10 mg once daily, Perindopril 8 mg once daily, Trandolapril 4 mg once daily, Benazepril 40 mg once daily, Fosinopril 40 mg once daily, Quinapril 20 mg twice daily 1

The American College of Cardiology recommends the following target doses for ARBs: Candesartan 32 mg once daily, Losartan 100 mg once daily, Valsartan 160 mg twice daily, Irbesartan 300 mg once daily, Telmisartan 80 mg once daily, Olmesartan 40 mg once daily, Azilsartan 80 mg once daily 1, 3, 4

The American College of Cardiology and European Journal of Heart Failure recommend a target dose of Sacubitril/valsartan 97/103 mg twice daily for patients with HFrEF 1, 5

The American College of Cardiology recommends the following target doses for beta-blockers: Bisoprolol 10 mg once daily, Carvedilol 25 mg twice daily, Carvedilol extended release 80 mg once daily, Metoprolol succinate sustained release 200 mg once daily 1

The American College of Cardiology recommends the following target doses for MRAs: Spironolactone 25-50 mg once daily, Eplerenone 50 mg once daily 2, 6

The American College of Cardiology recommends the following target doses for SGLT2 inhibitors: Dapagliflozin 10 mg once daily, Empagliflozin 10 mg once daily 7

Studies have shown a dose-response relationship between GDMT and improved outcomes, with higher doses providing greater benefits than lower doses 1, 2, 5
The European Journal of Heart Failure notes that despite guideline recommendations, the percentage of patients achieving target doses remains low in clinical practice 1, 8

The American College of Cardiology recommends initiating GDMT at low doses and titrating upward to target doses, with therapies adjusted no more frequently than every 2 weeks 1, 2, 3
The American College of Cardiology and Circulation recommend that beta-blockers be initiated at very low doses, followed by gradual incremental increases if lower doses have been well tolerated 1, 9

The American College of Cardiology recommends that patients receive at least 50% of the target dose of each medication class for adequate treatment effect, with examples including ACE inhibitors (e.g., enalapril 10 mg daily), ARBs (e.g., valsartan 160 mg daily), beta-blockers (e.g., carvedilol 25 mg daily), and ARNI (sacubitril/valsartan 49/51 mg twice daily) 1, 9

The American College of Cardiology and European Journal of Heart Failure recommend making every effort to achieve target doses shown to be effective in major clinical trials, with dose reduction only necessary due to side effects and attempts to restore target doses when possible 1, 5, 3
The European Journal of Heart Failure notes that approximately 40% of patients who required temporary dose reduction were subsequently restored to target doses 5

The European Journal of Heart Failure emphasizes that adverse events are common in heart failure patients but are often not attributable to GDMT, with rates of adverse events similar between active medication and placebo in clinical trials 10
The European Journal of Heart Failure notes that the approach to treating heart failure differs from treating cancer, with heart failure treatment often prioritizing avoidance of adverse effects over aggressive dosing, despite heart failure being more lethal than most forms of cancer 5

The European Society of Cardiology recommends reaching trial-proven target doses to reduce mortality in heart failure patients, not symptom control or biomarker levels 11, 12
Target doses reduce all-cause mortality by 73% compared to no treatment in heart failure patients 12
The American College of Cardiology suggests that asymptomatic changes in vital signs and laboratory values should NOT prevent uptitration in heart failure patients 13
Clinical stability does NOT eliminate the need for target doses in heart failure patients—the disease progresses silently even when symptoms are controlled 11

The European Society of Cardiology recommends dramatically different doses for heart failure versus hypertension, such as Valsartan: 40-80 mg daily for hypertension vs. 320 mg daily for heart failure 14
The American College of Cardiology suggests that Candesartan: 4-8 mg daily for hypertension vs. 32 mg daily for heart failure 14
The European Society of Cardiology recommends Losartan: 50 mg daily for hypertension vs. 150 mg daily for heart failure 14
The American College of Cardiology suggests that Metoprolol succinate: 25-100 mg daily for hypertension vs. 200 mg daily for heart failure 14
The European Society of Cardiology recommends Enalapril: 10-40 mg daily for hypertension vs. 10 mg twice daily for heart failure 15

The European Society of Cardiology recommends a mandatory, protocol-driven approach for heart failure patients, with planned intervals (every 1-2 weeks) until target dose is reached 13, 12, 15, 16
The American College of Cardiology suggests that 70-85% of heart failure patients can tolerate target doses when proper protocols are followed 12
Temporary dose reductions should be followed by restoration attempts—40% of heart failure patients successfully return to target doses 17

The European Society of Cardiology recommends monitoring blood pressure, heart rate, renal function, and potassium levels in heart failure patients, but these should NOT prevent uptitration unless severe 11, 12, 15
The American College of Cardiology suggests that symptoms are NOT reliable indicators—disease progresses despite symptom stability in heart failure patients 11

The European Society of Cardiology recommends that modest creatinine increases should be managed without dose reduction in heart failure patients; only severe dysfunction requires adjustment 11, 15
The American College of Cardiology suggests that asymptomatic hypotension should NOT prevent uptitration in heart failure patients 11, 17

Despite clear evidence, <25% of heart failure patients ever reach target doses in clinical practice, compared to >70% in clinical trials, representing a massive treatment gap driven by physician fears, clinical inertia, and misunderstanding of the dose-response relationship 17, 13, 11, 14